Han Zhu
hanzhumd.bsky.social
Han Zhu
@hanzhumd.bsky.social
Cardiologist and #PhysicianScientist at Stanford. Director, Stanford Translational Cardio-Oncology. Cardio-Immunology. MIT and CWRU alum.
Pinned
Proud to share this new pub from my lab - “Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis” www.ahajournals.org/doi/10.1161/.... Congrats to first authors Vivian Huang and Yin Sun. Our first foray into targeted therapy for this devastating autoimmune condition
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis | Circulation Research
BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardi...
www.ahajournals.org
Thrilled to receive NOA of our 2nd @NIH NHLBI R01. We propose a strategy to target ICI myocarditis & preserve critical tumor killing. Grateful to our lab members & collaborators. @StanfordCVI #CardioOnc We are recruiting new postdocs👉https://www.hanzhulab.com/about-6 @stanfordcvi.bsky.social
September 22, 2025 at 11:36 PM
It was great working with @seanmwu.bsky.social and @aliraissadati.bsky.social on this seminal work investigating the proof of concept use cell free mRNA biomarkers in ici myocarditis, a technology that can be expanded to other CV diseases! @stanfordmedicine.bsky.social @scvi-mavens.bsky.social
August 18, 2025 at 5:23 PM
Thrilled to share this new clinical paper from my lab led by Evaline Cheng, Maja Ivanovic, and Sarah Waliany published in JACC Journals JACC: CardioOncology this week - "Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy." lnkd.in/gRugNzuv Congrats, team!
August 16, 2025 at 4:17 PM
My lab is thrilled to receive the AHA Transformational Project award for our project, “Investigating Cardiac Fibroblast-T cell crosstalk in Immunotherapy Myocarditis”. Proud of Noah for his hard work on this project @ahascience.bsky.social @stanfordmedicine.bsky.social @stanfordcvi.bsky.social
July 22, 2025 at 2:10 PM
Finished up another amazing @SarnoffCardio annual meeting with friends, colleagues and mentors. So much great science and catching up. Looking forward to next year! @AmirZMunir @cardiooncology.bsky.social @AartiAsnaniMD @baik_alan @RonglihL @stanfordcvi.bsky.social @ucsfcardiology.bsky.social
May 4, 2025 at 5:46 PM
Reposted by Han Zhu
Look forward to @hanzhumd.bsky.social's talk for our
@YaleCardiology #cardioonc seminar @yalemed.bsky.social
@Yale @yalecancer.bsky.social on 4/29/25, 1-2pm EST.
April 28, 2025 at 5:27 PM
Excited to have @jennkwanMDPhD come talk at our Stanford Cardio-Onc conference today at 4-5 pm PST on Zoom! See you all there! @Paul_P_Cheng @StanfordCVI @SeanM_Wu @Ron_Witteles #cardioonc
March 11, 2025 at 6:58 PM
Reposted by Han Zhu
Protecting the Heart During the Fight Against Cancer
cvi.stanford.edu
February 21, 2025 at 6:03 PM
Reposted by Han Zhu
The Stanford Translational Cardio-Oncology Program focuses on reducing #cardiotoxicity across a spectrum of cancer therapies. Read more: med.stanford.edu/cancer/about... #CancerResearch #CancerRisk @hanzhumd.bsky.social
Guardians of the heart: Reducing cardiotoxicity in cancer treatment
The Stanford Translational Cardio-Oncology Program focuses on reducing cardiotoxicity across a spectrum of cancer therapies.
med.stanford.edu
February 20, 2025 at 5:34 PM
It was an honor to give cardiology grand rounds @umichCVC! I really enjoyed my visit, and it was exciting to share our recent work in the field of #cardioonc/#cardioimmunology and talk to new collaborators. Thanks so much for the warm welcome, and I look forward to future visits!
February 13, 2025 at 7:50 PM
Proud to share this new pub from my lab - “Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis” www.ahajournals.org/doi/10.1161/.... Congrats to first authors Vivian Huang and Yin Sun. Our first foray into targeted therapy for this devastating autoimmune condition
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis | Circulation Research
BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardi...
www.ahajournals.org
February 11, 2025 at 12:05 PM
First post on this app. Flying out from #AHA24. What an amazing conference, catching up with friends, colleagues and trainees. Good science, company, and food - what could be better? 🤓😊Looking forward to next year! @ahascience.bsky.social
November 18, 2024 at 8:40 PM